Based on the landmark KEYNOTE-859 trial, the FDA has approved pembrolizumab for advanced gastric cancer patients with PD-L1 CPS ≥1, demonstrating significant survival benefits (mOS: 13.0 months vs 11.4 months; HR=0.74, 95%CI 0.65-0.84). Here, CD274 is linked to gastric cancer.